SEK 0.01
(4.55%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.14 SEK | 68.89% |
2022 | -0.45 SEK | -28.57% |
2021 | -0.35 SEK | -6.06% |
2020 | -0.33 SEK | 17.5% |
2019 | -0.40 SEK | -73.91% |
2018 | -0.23 SEK | -9.52% |
2017 | -0.21 SEK | -534.44% |
2016 | -0.03 SEK | 0.0% |
2015 | - SEK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.00 SEK | 126.17% |
2024 Q2 | 0.02 SEK | 578.57% |
2023 Q1 | -0.05 SEK | 41.8% |
2023 FY | - SEK | 68.89% |
2023 Q3 | -0.04 SEK | 84.85% |
2023 Q4 | -0.01 SEK | 72.84% |
2023 Q2 | -0.26 SEK | -391.49% |
2022 Q2 | -0.36 SEK | 10.0% |
2022 Q1 | -0.40 SEK | -90.48% |
2022 FY | - SEK | -28.57% |
2022 Q4 | -0.09 SEK | 71.59% |
2022 Q3 | -0.32 SEK | 11.11% |
2021 FY | - SEK | -6.06% |
2021 Q1 | -0.08 SEK | 83.92% |
2021 Q3 | -0.11 SEK | -15.18% |
2021 Q4 | -0.21 SEK | -90.91% |
2021 Q2 | -0.10 SEK | -23.7% |
2020 FY | - SEK | 17.5% |
2020 Q3 | -0.11 SEK | -36766.67% |
2020 Q4 | -0.48 SEK | -336.36% |
2020 Q2 | 0.00 SEK | 100.3% |
2020 Q1 | -0.10 SEK | 81.3% |
2019 Q2 | -0.12 SEK | -46.88% |
2019 Q1 | -0.08 SEK | 31.92% |
2019 FY | - SEK | -73.91% |
2019 Q4 | -0.53 SEK | -664.79% |
2019 Q3 | -0.07 SEK | 42.25% |
2018 Q2 | -0.06 SEK | 11.03% |
2018 FY | - SEK | -9.52% |
2018 Q4 | -0.12 SEK | 14.29% |
2018 Q3 | -0.14 SEK | -122.58% |
2018 Q1 | -0.07 SEK | 62.79% |
2017 Q2 | -0.20 SEK | 0.0% |
2017 Q3 | -0.19 SEK | 5.0% |
2017 FY | - SEK | -534.44% |
2017 Q1 | -0.20 SEK | 0.0% |
2017 Q4 | -0.19 SEK | 0.0% |
2016 FY | - SEK | 0.0% |
2015 FY | - SEK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AddLife AB (publ) | 1.56 SEK | 108.974% |
Biotage AB (publ) | 3.33 SEK | 104.204% |
Bonesupport Holding AB (publ) | 3.77 SEK | 103.714% |
Doxa AB (publ) | 0.60 SEK | 123.333% |
Elekta AB (publ) | 3.41 SEK | 104.106% |
iZafe Group AB (publ) | -0.14 SEK | -0.0% |
Ortivus AB (publ) | -0.41 SEK | 65.854% |
Ortivus AB (publ) | -0.41 SEK | 65.854% |
Q-linea AB (publ) | -3.48 SEK | 95.977% |
Synsam AB (publ) | 2.09 SEK | 106.699% |